Recent Quotes (30 days)

You have no recent quotes
chg | %

Silence Therapeutics plc  

(Public, LON:SLN)   Watch this stock  
Find more results forSLN
134.00
+6.12 (4.79%)
Jul 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 125.60 - 134.75
52 week 71.88 - 134.75
Open 129.00
Vol / Avg. 119,916.00/17,184.00
Mkt cap 95.95M*
P/E     -
Div/yield     -
EPS -0.12*
Shares 69.99M
Beta     -
Inst. own     -
*GBP
Sep 25, 2017
Half Year 2017 Silence Therapeutics PLC Earnings Release (Estimated) - 8:00am BST - Add to calendar
Jun 16, 2017
Silence Therapeutics PLC Annual Shareholders Meeting (Estimated)
Jun 2, 2017
Silence Therapeutics PLC Annual Shareholders Meeting
  

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -481.43% -1096.10%
Operating margin -673.90% -1546.23%
EBITD margin - -1505.97%
Return on average assets -12.88% -14.39%
Return on average equity -13.24% -14.73%
Employees 59 -
CDP Score - -

Address

72 Hammersmith Road
LONDON, W14 8TH
United Kingdom - Map
+44-20-34576900 (Phone)
+44-7-957318494 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. The Company's RNA interference (RNAi) platform is AtuRNAi. AtuRNAi is based on specific small interfering RNA (siRNA) modules, stabilization technology and other tailored features. The Company's technology is in the clinic in a Phase IIa pancreatic cancer trial. The Company has developed modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutic RNA molecules.

Officers and directors

Ali Mortazavi Chief Executive Officer, Director
David Ellam Chief Financial Officer, Director
Lars Karlsson Head of Research and Development, Executive Director
Age: 54
Mark Cameron Head of Chemistry
Stephen B. Parker Independent Non-Executive Chairman of the Board
Age: 57
Stuart J.M. Collinson Ph.D. Non-Executive Director
Age: 54
Alistair William Gray Non-Executive Director
Age: 67